Microbiology Division, CSIR-Central Drug Research Institute (CDRI), B 10/1, Sector-10, Jankipuram Extension, Sitapur Road, Lucknow, 226 031, India,
Appl Biochem Biotechnol. 2013 Oct;171(4):927-38. doi: 10.1007/s12010-013-0400-2. Epub 2013 Aug 3.
Microbial metabolites have many important applications in pharmaceutical and health-care industry. The products of microbial origin are usually produced by submerged fermentation. The solid-state fermentation represents an alternative mode of fermentation, which is increasingly being employed as an alternative to submerged fermentation for metabolite production. The prospect of producing high-value product using low-value raw material offers a substantial premium to switch to these technologies. The cost of statins being one major factor, solid-state fermentation with agro-industrial residues as carbon, nitrogen and support matrix, promises to substantially lower the cost of production. Hence, newer approaches are required to exploit the agro-industrial residues for statin production. The development of these technologies offers an opportunity to exploit low-cost substrates without substantial investment in newer production methodologies. The emerging evidence of beneficial effect of statins in applications other than lipid lowering such as in Alzheimer disease, HIV, age-related dementia, and cancer chemotherapy makes it very important to develop methods for economic production of statins.
微生物代谢产物在医药和保健行业有许多重要的应用。微生物来源的产品通常通过液体深层发酵生产。固态发酵是一种替代发酵方式,越来越多地被用作代谢产物生产的替代方法,以取代液体深层发酵。利用低价值原料生产高价值产品的前景为向这些技术转变提供了巨大的优势。他汀类药物的成本是一个主要因素,利用农业工业废料作为碳、氮和支持基质的固态发酵,有望大幅降低生产成本。因此,需要采用新方法来利用农业工业废料生产他汀类药物。开发这些技术为利用低成本基质提供了机会,而无需在更新的生产方法上进行大量投资。他汀类药物在降低血脂以外的其他应用(如阿尔茨海默病、HIV、年龄相关性痴呆和癌症化疗)方面的有益作用的新证据表明,开发经济生产他汀类药物的方法非常重要。